Sovateltide not checked
Pharmazz, Inc. · PMZ-1620 · SPI-1620
FollowEvery change as it happens, and a Monday email
Trials
5 active
10 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was…”In the company’s words, NCT05955326 on ClinicalTrials.gov
- Tested for
- Acute Cerebral Ischemia, Acute Ischemic Stroke, Cerebral Stroke, Traumatic Brain Injury, Acute Spinal Cord Injury, Hypoxic-Ischemic Encephalopathy, Neonatal Asphyxia, Neonatal Encephalopathy
- Main trialPhase 4
- “This is a prospective, multicenter, randomized, double-blind, parallel, phase IV study designed to evaluate the safety and efficacy of sovateltide (PMZ-1620, IRL-1620) as a potential treatment for cerebral ischemic stroke.”In the company’s words, NCT05955326 on ClinicalTrials.gov
- Other names
- PMZ-1620 · SPI-1620 · IRL-1620 · Tycamzzi · Tyvalzi
Other drugs for Acute Cerebral Ischemia
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- DM199DiaMedica Therapeutics Inc · Phase 2/3
- CenvacibartRegeneron · Phase 3
- REGN9933Regeneron · Phase 3
- SP-8203Shin Poong Pharmaceutical Co. Ltd. · Phase 3
- SHPL-49Shanghai Hutchison Pharmaceuticals Limited · Phase 3
Coming up4
- NovPhase 2 trial completes · ClinicalTrials.gov
- 18 DecPhase 4 trial completes · ClinicalTrials.gov
- Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- Feb 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 18 Dec 2026 | Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | |
| Phase 3Recruiting | Sep 2027 | Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | |
| Phase 3Not yet recruiting | Feb 2028 | Sovateltide for the Treatment of Acute Traumatic Brain Injury | |
| Phase 2Recruiting | Jun 2026 | PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury | |
| Phase 2Recruiting | Nov 2026 | Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy | |
| Phase 3Completed | 10 Feb 2022 | Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke | |
| Phase 2Terminated | Jul 2015 | Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) | |
| Phase 2Terminated | Sep 2015 | Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer | |
| Phase 2Completed | 12 Apr 2019 | PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients | |
| Phase 2Completed | 20 Dec 2022 | PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026